Tier 2 — strong

Potential Adjunctive Effects of Quercetin-Curcumin Co-Supplementation in Adults with Mild-to-Moderate Long COVID: Results from a Pragmatic Exploratory Real-World Clinical Study

Amjad Khan, Fazle Rabbani, Sami Ullah Mumtaz, Roha Javed, Ikram Ujjan, Ayesha Kanwal, Gabriele Conti
Pharmaceuticals (Basel, Switzerland) 2026 19(8):1202

Bibliography

PubMed
PMID 42653699
PubMed Central
PMC13516766
DOI
10.3390/ph19081202
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
Reported disclosure: The authors declare no conflicts of interest.

Study snapshot

DesignSingle-arm open-label exploratory real-world study
ModelHuman intervention research
Sample15 adults with long COVID
InterventionQuercetin 65 mg and curcumin 42 mg per capsule; two capsules twice daily alongside usual care
Duration8 weeks
EndpointsSymptoms and quality of life

What the study showed, in plain terms

Published in 2026, this source examined immunity and respiratory health. Design: Single-arm open-label exploratory real-world study. Sample/model: 15 adults with long COVID. The exposure or intervention was Quercetin 65 mg and curcumin 42 mg per capsule; two capsules twice daily alongside usual care. Follow-up or treatment period: 8 weeks.

Patient-reported symptom burden, fatigue, pain, and physical quality of life improved from baseline; several other outcomes were not significant.

No control group and two active ingredients. Natural recovery, expectations, and concurrent care cannot be separated from treatment effects.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Immune Health, Colds and COVID-19. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Patient-reported symptom burden, fatigue, pain, and physical quality of life improved from baseline; several other outcomes were not significant.
  • The recorded outcome domains were Symptoms and quality of life.
  • The result applies to the tested exposure: Quercetin 65 mg and curcumin 42 mg per capsule; two capsules twice daily alongside usual care; 8 weeks.

What this study can and cannot tell us

  • No control group and two active ingredients. Natural recovery, expectations, and concurrent care cannot be separated from treatment effects.
  • Without a sufficiently blinded concurrent control, time effects, expectations, co-interventions and regression toward the mean can explain part of an apparent improvement.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 1
Quercetin for the treatment of COVID-19 patients: A systematic review and meta-analysis
Huzaifa Ahmad Cheema et al. · Reviews in medical virology · 2023
Tier 1
The effect of quercetin supplementation on clinical outcomes in COVID-19 patients: A systematic review and meta-analysis
Somayeh Ziaei et al. · Food science & nutrition · 2023
Tier 2
Quercetin–bromelain supplementation and clinical outcomes of COVID-19: a randomized, double-blind, placebo-controlled trial in hospitalized patients in Tunisia
Marwa Gargouri et al. · BMC Pharmacology and Toxicology · 2026
Tier 2
Effect of oral treatment with quercetin on inflammatory and oxidative stress markers in patients with chronic obstructive pulmonary disease
Shivani Patel et al. · Pharmacological research. Natural products · 2025
Tier 2
Effectiveness of the quercetin use in patients with COVID-19 with concomitant type 2 diabetes mellitus
Zoriana Tylishchak et al. · Wiadomosci lekarskie (Warsaw, Poland : 1960) · 2024

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology